A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. [electronic resource]
Producer: 20110524Description: 121-6 p. digitalISSN:- 1433-8726
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antineoplastic Agents -- adverse effects
- Carcinoma, Renal Cell -- drug therapy
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Humans
- Interferon alpha-2
- Interferon-alpha -- adverse effects
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Prospective Studies
- Recombinant Proteins
- Retrospective Studies
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.